Braveheart Bio (NASDAQ:BRVE) Trading Down 5.2% - Here's Why

Key Points

• Braveheart Bio shares fell 5.2% in mid-day trading to about $26.02, with roughly 150,202 shares changing hands—53% below average volume.
• Analyst coverage was broadly positive: five firms rated the stock Buy or Overweight, with an average price target of $45.25 versus the current trading level.
• Insiders made substantial purchases, including a combined 3.86 million shares bought by a major shareholder and a director at $18 per share; insiders purchased 8.75 million shares worth about $157.5 million during the quarter.

Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) shares dropped 5.2% during mid-day trading on Monday . The company traded as low as $25.94 and last traded at $26.02. Approximately 150,202 shares changed hands during mid-day trading, a decline of 53% from the average daily volume of 318,614 shares. The stock had previously closed at $27.44.

Analysts Set New Price Targets

A number of research analysts have weighed in on BRVE shares. The Goldman Sachs Group began coverage on shares of Braveheart Bio in a research report on Monday. They set a "buy" rating and a $48.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Braveheart Bio in a report on Monday. They issued a "buy" rating and a $48.00 target price for the company. TD Cowen assumed coverage on shares of Braveheart Bio in a report on Monday. They set a "buy" rating on the stock. Cantor Fitzgerald started coverage on shares of Braveheart Bio in a report on Monday. They set an "overweight" rating and a $40.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a research report on Monday. They issued a "buy" rating and a $45.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $45.25.

Braveheart Bio Price Performance

Insider Transactions at Braveheart Bio

In related news, major shareholder Growth Opportunities F. Forbion purchased 1,920,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $34,560,000.00. Following the purchase, the insider directly owned 11,640,546 shares of the company's stock, valued at approximately $209,529,828. This represents a 19.75% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Erez Chimovits acquired 1,940,000 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the transaction, the director owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 8,751,942 shares of company stock valued at $157,534,956.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source